The use of thyroid hormone liothyronine in patients with heart failure
- Conditions
- Other forms of heart disease, Disorders of the thyroid glandNutritional, Metabolic, Endocrine
- Registration Number
- ISRCTN10706683
- Lead Sponsor
- Gateshead Health NHS Foundation Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 25
1. Men and women aged between 18 – 80 years
2. Stable HFrEF (no admission to hospital with HF exacerbations in the previous 3 months)
3. Chronic HFrEF (diagnosed more than 3 months prior to recruitment)
4. Moderate – severe systolic left ventricular dysfunction (LVEF < 45% on cardiac echocardiogram within last 6 months)
5. On standard HFrEF therapy
6. With low serum T3 levels (< 3.5 pmol/L)
1. Those on medications affecting thyroid function (such as levothyroxine, antithyroid drugs, amiodarone, lithium and sodium valproate)
2. Patients admitted to hospital with acute exacerbation of HF in the preceding 3 months
3. Claustrophobia precluding cardiac magnetic resonance (MR) assessment
4. Cardiac devices (such as implantable cardioverter defibrillators) that are incompatible with MR scanning
5. Untreated valvular heart disease as the main cause of the HFrEF
6. With severely abnormal serum TSH (< 0.1 or > 10.0 mIU/L) or thyroxine (FT4) levels (< 9.0 or > 23.0 pmol/L)
7. Participants who are unable to provide written informed consent
8. Individuals who are pregnant or trying to conceive
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method